Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

148 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanoma.
D'Angelo SP, Hamid OA, Tarhini A, Schadendorf D, Chmielowski B, Collichio FA, Pavlick AC, Lewis KD, Weil SC, Heyburn J, Schweizer C, O'Shannessy DJ, Carvajal RD. D'Angelo SP, et al. Among authors: schweizer c. Invest New Drugs. 2018 Feb;36(1):103-113. doi: 10.1007/s10637-017-0530-4. Epub 2017 Nov 11. Invest New Drugs. 2018. PMID: 29127533 Free PMC article. Clinical Trial.
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal Cancer.
Grothey A, Strosberg JR, Renfro LA, Hurwitz HI, Marshall JL, Safran H, Guarino MJ, Kim GP, Hecht JR, Weil SC, Heyburn J, Wang W, Schweizer C, O'Shannessy DJ, Diaz LA Jr. Grothey A, et al. Among authors: schweizer c. Clin Cancer Res. 2018 Jan 15;24(2):316-325. doi: 10.1158/1078-0432.CCR-17-1558. Epub 2017 Oct 30. Clin Cancer Res. 2018. PMID: 29084918 Clinical Trial.
Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study.
Konner JA, Bell-McGuinn KM, Sabbatini P, Hensley ML, Tew WP, Pandit-Taskar N, Vander Els N, Phillips MD, Schweizer C, Weil SC, Larson SM, Old LJ. Konner JA, et al. Among authors: schweizer c. Clin Cancer Res. 2010 Nov 1;16(21):5288-95. doi: 10.1158/1078-0432.CCR-10-0700. Epub 2010 Sep 20. Clin Cancer Res. 2010. PMID: 20855460 Clinical Trial.
Correlation of FCGRT genomic structure with serum immunoglobulin, albumin and farletuzumab pharmacokinetics in patients with first relapsed ovarian cancer.
O'Shannessy DJ, Bendas K, Schweizer C, Wang W, Albone E, Somers EB, Weil S, Meredith RK, Wustner J, Grasso L, Landers M, Nicolaides NC. O'Shannessy DJ, et al. Among authors: schweizer c. Genomics. 2017 Jul;109(3-4):251-257. doi: 10.1016/j.ygeno.2017.04.006. Epub 2017 Apr 25. Genomics. 2017. PMID: 28450240 Free article.
A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse.
Vergote I, Armstrong D, Scambia G, Teneriello M, Sehouli J, Schweizer C, Weil SC, Bamias A, Fujiwara K, Ochiai K, Poole C, Gorbunova V, Wang W, O'Shannessy D, Herzog TJ. Vergote I, et al. Among authors: schweizer c. J Clin Oncol. 2016 Jul 1;34(19):2271-8. doi: 10.1200/JCO.2015.63.2596. Epub 2016 Mar 21. J Clin Oncol. 2016. PMID: 27001568 Clinical Trial.
148 results